Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
20 06 2019
Historique:
received: 12 09 2018
accepted: 12 03 2019
pubmed: 25 3 2019
medline: 10 1 2020
entrez: 24 3 2019
Statut: ppublish

Résumé

Calreticulin (CALR) +1 frameshift mutations in exon 9 are prevalent in myeloproliferative neoplasms. Mutant CALRs possess a new C-terminal sequence rich in positively charged amino acids, leading to activation of the thrombopoietin receptor (TpoR/MPL). We show that the new sequence endows the mutant CALR with rogue chaperone activity, stabilizing a dimeric state and transporting TpoR and mutants thereof to the cell surface in states that would not pass quality control; this function is absolutely required for oncogenic transformation. Mutant CALRs determine traffic via the secretory pathway of partially immature TpoR, as they protect N117-linked glycans from further processing in the Golgi apparatus. A number of engineered or disease-associated TpoRs such as TpoR/MPL R102P, which causes congenital thrombocytopenia, are rescued for traffic and function by mutant CALRs, which can also overcome endoplasmic reticulum retention signals on TpoR. In addition to requiring

Identifiants

pubmed: 30902807
pii: S0006-4971(20)42473-5
doi: 10.1182/blood-2018-09-874578
doi:

Substances chimiques

Calreticulin 0
Molecular Chaperones 0
Receptors, Thrombopoietin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2669-2681

Subventions

Organisme : Austrian Science Fund FWF
ID : P 30041
Pays : Austria

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by The American Society of Hematology.

Auteurs

Christian Pecquet (C)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium.

Ilyas Chachoua (I)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Anita Roy (A)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Thomas Balligand (T)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium.

Gaëlle Vertenoeil (G)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Emilie Leroy (E)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium.

Roxana-Irina Albu (RI)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Jean-Philippe Defour (JP)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Harini Nivarthi (H)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Eva Hug (E)

MyeloPro Research and Diagnostics GmbH, Vienna, Austria.

Erica Xu (E)

MyeloPro Research and Diagnostics GmbH, Vienna, Austria.

Yasmine Ould-Amer (Y)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Céline Mouton (C)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Didier Colau (D)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Didier Vertommen (D)

Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Myat Marlar Shwe (MM)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.

Caroline Marty (C)

INSERM, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.
Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.
Gustave Roussy, Unité Mixte de Recherche 1170, Villejuif, France; and.

Isabelle Plo (I)

INSERM, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.
Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.
Gustave Roussy, Unité Mixte de Recherche 1170, Villejuif, France; and.

William Vainchenker (W)

INSERM, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.
Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.
Gustave Roussy, Unité Mixte de Recherche 1170, Villejuif, France; and.

Robert Kralovics (R)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Stefan N Constantinescu (SN)

Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
Université catholique de Louvain and de Duve Institute, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH